Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 4/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.39 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.38 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.36 |
| ▸ | VEGFA | P15692 | 2/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.35 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2821883 | 0.88 | HRH3 (0.39) | HRH3TBXA2REPAS1VEGFACYP19A1 | |
| SCHEMBL2821885 | 0.88 | HRH3 (0.39) | HRH3TBXA2REPAS1VEGFACYP19A1 | |
| SCHEMBL13413653 | 0.87 | SPHK2 (0.39) | SPHK2HRH3TBXA2REPAS1VEGFA | |
| SCHEMBL13630672 | 0.86 | TBXA2R (0.38) | SPHK2HRH3TBXA2REPAS1VEGFA | |
| SCHEMBL5519510 | 0.85 | TBXA2R (0.37) | SPHK2HRH3TBXA2REPAS1VEGFA | |
| SCHEMBL4369038 | 0.83 | OPRK1 (0.39) | HRH3TBXA2REPAS1VEGFAMCHR1 | |
| SCHEMBL2826322 | 0.82 | TBXA2R (0.42) | TBXA2REPAS1VEGFA | |
| Hydrochloric Acid SCHEMBL2820385 | 0.81 | TBXA2R (0.42) | TBXA2REPAS1VEGFA | |
| SCHEMBL3127977 | 0.81 | TRPV4 (0.39) | SPHK2TBXA2REPAS1VEGFACYP19A1 | |
| SCHEMBL3123218 | 0.80 | TBXA2R (0.41) | TBXA2REPAS1VEGFATRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206186-B2 | 2-phenoxy- and 2-phenylsulfonamide derivatives with CCR3 antagonistic activity for the treatment of inflammatory or immunological disorders | AXIKIN PHARMACEUTICALS, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-9206186-B2 | 2-phenoxy- and 2-phenylsulfonamide derivatives with CCR3 antagonistic activity for the treatment of inflammatory or immunological disorders | AXIKIN PHARMACEUTICALS, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20090286771-A1 | 2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Inflammatory or Immunological Disorders | LI YINGFU | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286771-A1 | 2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Inflammatory or Immunological Disorders | CCR3, CCR2, CCR1 | SPHK2 101/4885HRH3 15/4885TBXA2R 2956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.